secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001193125-25-270524
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics reports Q3 2025 net income of $5.9M, cuts FY revenue guidance to $115-118M
--------------------------------------------------------------------------------

- Q3 revenue $30.6M (+20% YoY), net income $5.9M (doubled), adjusted net income $8.8M.
- Full-year revenue guidance lowered to $115-118M from $118-128M due to Etorel rollout delays.
- Nine-month 2025 revenue $79.4M, net income $11.2M vs $17.3M YoY; basic EPS $0.08.
- Cash $80.3M as of Sept 30; completed Phase 3 pneumoconiosis trial enrollment (272 patients).
- Hydronidone NDA in China progressing; US IND for MASH delayed to 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/0001193125-25-270524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000119312525270524/gyre-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-270524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer